Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Terminated
Trial end date:
2016-05-09
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of ganetespib when given
together with paclitaxel and to see how well they work in treating patients with recurrent
ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as
paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Ganetespib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Giving paclitaxel and ganetespib may be
an effective treatment for ovarian, fallopian tube, or primary peritoneal cancer.